Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Velinotamig in Relapsing and Refractory ITP and wAIHA
NCT07738822Phase 2Not yet recruiting
- Sponsor
- Cullinan Therapeutics
- Start
- Dec 2026
- Primary completion
- Jan 2029
- Countries
- 1
01
Overview
Phase 2, open-label trial of velinotamig in immune thrombocytopenia (ITP) and warm autoimmune hemolytic anemia (wAIHA) (2 arms), sponsored by Cullinan Therapeutics. Primary endpoint: Safety and Tolerability at 48 weeks. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
velinotamig
03
Conditions
immune thrombocytopenia (ITP)warm autoimmune hemolytic anemia (wAIHA)
Beyond the preview
Go deeper on NCT07738822.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07738822.